Brief: Acumen Pharmaceuticals Says Presents Positive Topline Results From First-In-Human Phase 1 Study Of ACU193 For Early Alzheimer's Disease

Acumen Pharmaceuticals

16/07/2023 08:14

July 16 (Reuters) - Acumen Pharmaceuticals Inc  ABOS.O :
    * PRESENTS POSITIVE TOPLINE RESULTS FROM FIRST-IN-HUMAN
PHASE 1
STUDY OF ACU193 FOR EARLY ALZHEIMER'S DISEASE
    * ACU193 WAS WELL-TOLERATED IN PATIENTS WITH EARLY
ALZHEIMER'S
DISEASE,RESULTED IN NO DRUG-RELATED SERIOUS ADVERSE EVENTS,
    * TOPLINE RESULTS FROM INTERCEPT-AD TRIAL MET PRIMARY AND
SECONDARY OBJECTIVES, DEMONSTRATING PROOF-OF-MECHANISM FOR
ACU193

Source text for Eikon:  ID:nGNX4Xbfz8 
Further company coverage:  ABOS.O 

 ((Reuters.Briefs@thomsonreuters.com;))